期刊文献+

白塞病相关性眼病的研究进展 被引量:3

Research progress of oculopathy associated with Behcet's disease
下载PDF
导出
摘要 白塞病是一种慢性、累及多系统的自身免疫性疾病,典型的临床特征有复发性口腔溃疡、阴部溃疡、眼炎等,也可累及胃肠道、关节、心血管、肾脏及神经等多个系统。其基本病理改变为非特异性血管炎,可累及大小动脉、静脉及毛细血管,多数以小血管和静脉为主,大多为渗出性,少数为增生性,有时两者同时存在,病变部位可以发生充血、水肿、栓塞、狭窄、纤维素渗出和脓疡形成等。其中眼部受累者预后不佳,常表现为葡萄膜炎,且反复发作,以青壮年多见,常引起一些并发症,严重影响视力。本文从临床特点、发病机制、治疗方面对白塞病相关性眼病进行综述。 Behcet's disease is a chronic autoimmune disease involving multiple systems. The typical clinical characteristics are recurrent oral ulcers, pudendal ulcer and ophthalmia. It could also affect multiple parts of the body including gastrointestinal tract, joint, heart and blood vessels, kidney and nerves. The basic pathological changes are nonspecific vasculitis involving arteria, veins and capillaries and mainly happen in small vessels and veins. Most of them are exudative, some of them are proliferative and sometimes they are exudative and proliferative at the same time. Congestion, edema, embolism, stenosis, fibrous exudation and abscess could occur in the diseased region. The prognosis is poor when eye is involved. The common symptom is uveitis with recurrent attacks. It usually occurs in young adults and causes some complication. It could badly affect vision. The clinical characteristics, mechanisms and treatments of oculopathy associated with Behcet's disease were reviewed in this paper.
作者 柴改琴 陈茜茜 卫丽君 孙晓涛 石磊 李军霞 CHAI Gaiqin;CHEN Qian qian;WEI Lijun;SUN Xiaotao;SHI Lei;LI Junxia(Shanxi Medical University,Taiyuan 030000,China;Department of Rheumatology,Second Hospital of Shanxi Medical University,Taiyuan 030000,China)
出处 《中国现代医生》 2018年第18期152-155,共4页 China Modern Doctor
基金 山西省回国留学人员科研资助项目(2016-124)
关键词 白塞病 眼炎 HLA-B51 生物制品 Behcet's Disease Ophthalmia HLA-BS1 Biologicals
  • 相关文献

参考文献4

二级参考文献63

  • 1杨永升,庄曾渊.Behet病的免疫学研究进展[J].国外医学(眼科学分册),2005,29(2):99-103. 被引量:7
  • 2汪运山,刘宗印,高雁翎.一种高纯度染色体DNA快速制备法[J].现代妇产科进展,1995,4(1):80-81. 被引量:2
  • 3Calguneri M, Ertenli I, Kiraz S, et al. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet's disease. Dermatology, 1996,192 : 125 - 128.
  • 4Yazici H, Pazarli H, Barnes CG, et al. A controlled trim of azathioprine in Behcet's syndrome. N Engl J Med, 1990, 322:281 -285.
  • 5Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum, 1997,40:769 - 774.
  • 6Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized,double-blind, placebo-controlled trial. Ann Intern Med, 1998, 128:443 - 450.
  • 7O'Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease. Am J Med, 1984, 76:75-84.
  • 8Masuda K, Nakajima A, Urayama A, et al. Double-masked trim of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet, 1989, 1:1093-1096.
  • 9Whitcup SM, Salvo EC Jr, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease. Am J Ophthalmol, 1994, 118:39-45.
  • 10Hamuryudan V, Moral F, Yurdakul S, et al. Systemic interferon alpha 2b treatment in Behcet's syndrome. J Rheumatol, 1994,21 : 1098- 1100.

共引文献29

同被引文献65

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部